Trial Profile

Double-blind, Placebo Controlled, First in Human Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Ascending Oral Doses of YCT-529

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 07 Oct 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

03 Jun 2024 Status changed from recruiting to completed, according to a YourChoice Therapeutics media release.
03 Jun 2024 According to a YourChoice Therapeutics media release, results of the phase 1a study will be presented at the 2024 BIO International Convention on June 4 at 10:45 PDT.
19 Mar 2024 According to a YourChoice Therapeutics media release, the company provided an update from this study at the American Chemical Society (ACS) 2024 Spring Meeting. And, expects to complete the study by mid-2024.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com